CATALOGO DEI PRODOTTI DELLA RICERCA

Carbone, Carmine
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.900
EU - Europa 2.841
AS - Asia 1.894
SA - Sud America 245
Continente sconosciuto - Info sul continente non disponibili 90
AF - Africa 55
OC - Oceania 9
Totale 8.034
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.831
RU - Federazione Russa 1.002
SG - Singapore 670
CN - Cina 628
GB - Regno Unito 466
IT - Italia 395
DE - Germania 264
BR - Brasile 188
VN - Vietnam 187
HK - Hong Kong 184
FI - Finlandia 160
SE - Svezia 159
IE - Irlanda 128
FR - Francia 117
KR - Corea 57
CA - Canada 36
NL - Olanda 33
JP - Giappone 26
UA - Ucraina 26
BD - Bangladesh 25
TR - Turchia 24
AR - Argentina 21
IN - India 21
MX - Messico 20
ES - Italia 18
ID - Indonesia 18
BE - Belgio 15
ZA - Sudafrica 15
AT - Austria 14
PL - Polonia 13
JO - Giordania 10
NG - Nigeria 10
PY - Paraguay 9
AU - Australia 8
CO - Colombia 8
EC - Ecuador 8
MA - Marocco 7
BJ - Benin 5
IQ - Iraq 5
PH - Filippine 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
EG - Egitto 4
LT - Lituania 4
PK - Pakistan 4
TG - Togo 4
VE - Venezuela 4
CL - Cile 3
CR - Costa Rica 3
EU - Europa 3
GR - Grecia 3
HR - Croazia 3
KE - Kenya 3
PE - Perù 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
BY - Bielorussia 2
GD - Grenada 2
GT - Guatemala 2
HN - Honduras 2
KZ - Kazakistan 2
LK - Sri Lanka 2
NP - Nepal 2
PS - Palestinian Territory 2
SN - Senegal 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BT - Bhutan 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
JM - Giamaica 1
KH - Cambogia 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MG - Madagascar 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 7.948
Salva come PNG Salva come JPEG
Città #
Southend 389
Ashburn 371
Chandler 357
Moscow 353
Singapore 348
Dallas 261
San Jose 254
Hong Kong 175
Verona 165
Woodbridge 152
Dublin 128
Munich 127
Jacksonville 125
Beijing 118
Helsinki 93
The Dalles 79
Ann Arbor 75
New York 68
Council Bluffs 58
Jinan 53
Ho Chi Minh City 51
Los Angeles 45
Hanoi 43
Houston 41
Wilmington 40
Lawrence 38
Princeton 38
Redmond 37
Nanjing 34
Shenyang 33
Tianjin 31
Tokyo 25
Hebei 24
Redondo Beach 22
São Paulo 22
Santa Clara 21
Turku 21
Dong Ket 20
Buffalo 17
Milan 17
Nanchang 17
London 16
Orem 16
Brussels 15
Frankfurt am Main 15
Haikou 15
Taiyuan 15
Atlanta 14
Columbus 14
Guangzhou 14
Montreal 14
Zhengzhou 14
Jakarta 13
Seattle 13
Sindelfingen 13
Bologna 11
Changsha 11
Johannesburg 11
Ningbo 11
Warsaw 11
Abuja 10
Boardman 10
Lappeenranta 10
Brooklyn 9
Chennai 9
Chicago 9
Jiaxing 9
Madrid 9
Redwood City 9
Rio de Janeiro 9
Toronto 9
Vienna 9
Washington 9
Amman 8
Denver 8
Hangzhou 8
Kent 8
Phoenix 8
San Francisco 8
Amsterdam 7
Biên Hòa 7
Da Nang 7
Manchester 7
Mexico City 7
Norwalk 7
Nuremberg 7
Querétaro 7
Stockholm 7
Ankara 6
Asunción 6
Barnet 6
Brasília 6
Haiphong 6
Jyväskylä 6
Paris 6
Seoul 6
Taizhou 6
Belo Horizonte 5
Boston 5
Cotonou 5
Totale 4.942
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 317
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 314
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 292
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3 267
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 260
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 258
Unraveling the role of lymph node metastasis in PDAC and dCCA progression 255
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 236
NF-κB as a target for pancreatic cancer therapy. 214
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 211
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 205
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer 200
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 196
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 194
Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC 193
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 192
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 188
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 186
Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia 181
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 180
Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype 178
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 173
PEROXIREDOXIN-2: A NOVEL REGULATOR OF IRON HOMEOSTASIS IN INEFFECTIVE ERYTHROPOIESIS 170
EMT and Treatment Resistance in Pancreatic Cancer 164
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance 163
Local ablation disrupts immune evasion in pancreatic cancer 161
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer 159
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity 155
Molecular alterations in basal cell carcinoma subtypes 155
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 154
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 150
Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC 144
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy 144
Toll-Like Receptor 9 Agonists for Cancer Therapy 144
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer 141
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation 137
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion 135
MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC 131
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 125
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus 122
Rationale and clinical use of multitargeting anticancer agents. 101
Systemic profile of immune factors in an elderly Italian population affected by chronic strongyloidiasis 88
Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat 82
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors 79
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer 77
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story 63
Totale 8.034
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.975
article - articoli 24.777
book - libri 0
conference - conferenze 1.408
curatela - curatele 0
other - altro 790
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.950
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022396 0 150 17 37 11 5 8 24 9 12 19 104
2022/2023820 70 104 75 149 52 200 4 46 96 7 11 6
2023/2024491 13 22 36 54 52 71 27 77 6 35 73 25
2024/20251.292 51 55 51 174 55 78 120 88 213 78 117 212
2025/20263.435 212 161 286 552 876 219 315 170 266 219 94 65
2026/202745 32 13 0 0 0 0 0 0 0 0 0 0
Totale 8.034